Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Gastric Bypass Surgery May Increase Risk of Kidney Stones

By HospiMedica staff writers
Posted on 14 Jul 2008
Roux-en-Y gastric bypass (RYGB), a surgical treatment for morbid obesity, appears to increase the risk of calcium oxalate kidney stones, according to a new study.

Researchers at the University of Minnesota Medical School (Minneapolis, USA) conducted a retrospective and cross-sectional study that involved 24 morbidly obese adults who underwent RYGB surgery between December 2005 and April 2007. More...
Patients provided 24-hour urine collections for analysis 7 days before and 90 days after operation. Primary outcomes were changes in 24-hour urinary oxalate excretion and relative supersaturation of calcium oxalate from baseline to three months post-RYGB.

The researcher found that RYGB was associated with a significant increase in urinary oxalate excretion when compared with baseline. The procedure was also linked to relative supersaturation of calcium oxalate in six patients (25%). De novo hyperoxaluria was noted in several patients; the researchers were unable to identify any preoperative factors that predicted which patients would develop de novo hyperoxaluria or the magnitude of the increase in daily oxalate excretion. The study was published in the June 2008 edition of the Journal of the American College of Surgeons.

"This is the first study to demonstrate how rapid the changes in urinary risk for kidney stones occur,” said lead author Manoj Monga, M.D., of the department of urologic surgery. "This was surprising as previous studies have suggested it takes up to one year before the increase in oxalate is noted. The reason for the difference in our observation is that this is the first study to look at the three-month time point.”

In Roux-en-Y gastric bypass (RYGB), the stomach is reduced by creating a small pouch at the top of the stomach using surgical staples or a lap-band. The smaller stomach is connected directly to the middle portion of the small intestine (jejunum), bypassing the rest of the stomach and the upper portion of the small intestine (duodenum). RYGB was developed when patients treated for obesity with jejunoileal bypass (JIB, now replaced with other options) experienced a marked increased risk of hyperoxaluria, nephrolithiasis, and oxalate nephropathy.


Related Links:
University of Minnesota Medical School

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Electric Bed
DIXION Intensive Care Bed
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.